Pharmacodynamic and Pharmacokinetic Equivalences of Epoetin Hospira and Epogen(®) After Multiple Subcutaneous Doses to Healthy Male Subjects.
The purpose of this study was to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) equivalences of multiple doses of the proposed biosimilar Epoetin Hospira to the reference product Epogen(⁎), when each is administered three times per week over 28 days to healthy male subjects



This single center, open-label, randomized, parallel group study was conducted in 129 healthy male subjects. Subjects were randomized to receive 100 U/kg Epoetin Hospira or 100 U/kg Epogen, each administered subcutaneously 3 times per week over 28 days. Blood was collected for determination of hemoglobin (Hb) concentrations for PD properties and for determination of epoetin concentrations for PK properties. The primary PD end point was the geometric mean ratio (GMR) of the 2 treatments for area under the effect curve for Hb from day 1 through 48 hours after the final dose of study drug administration on day 26, and the primary PK end point was the GMR of the 2 treatments for AUC0-48 and Cmax for epoetin after the final dose of study drug on day 26.



The GMR (Epoetin Hospira/Epogen) for the area under the effect curve for Hb from day 1 through 48 hours after the final dose of study drug administration on day 26 was 1.006 with a 95% CI of 0.996 to 1.016, which was contained within the prespecified equivalence margin of 0.965 to 1.035. The GMRs (Epoetin Hospira/Epogen) for the epoetin-derived PK parameters were 0.974 for AUC0-48 with a 90% CI of 0.896 to 1.059, and 0.938 for Cmax with a 90% CI of 0.839 to 1.049, with both 90% CIs contained within the prespecified equivalence margin of 0.80 to 1.25. The incidence (21.2% and 23.8% for Epoetin Hospira and Epogen, respectively) and severity of adverse events were similar between the 2 groups. One subject in each treatment group had a positive recombinant human erythropoietin antibody result by radioimmunoprecipitation assay before dosing and throughout study conduct with negative immunoglobulin M and neutralizing antibodies and with no evidence of clinical deterioration or of impact on PD, PK, or safety profile.



The results of this study established PD and PK equivalences of multiple subcutaneous doses of the proposed biosimilar Epoetin Hospira to the reference product Epogen in healthy male subjects, and supported the overall demonstration of biosimilarity of Epoetin Hospira and Epogen.
Global Clinical Development, Hospira, a Pfizer company, Lake Forest, Illinois. Electronic address: dennis.stalker@hospira.com.
Dennis
D
Stalker
Global Clinical Development, Hospira, a Pfizer company, Lake Forest, Illinois.
Atulkumar
A
Ramaiya
Global Clinical Development, Hospira, a Pfizer company, Lake Forest, Illinois.
Seema
S
Kumbhat
Global Clinical Development, Hospira, a Pfizer company, Lake Forest, Illinois.
Jeffrey
J
Zhang
Global Clinical Development, Hospira, a Pfizer company, Lake Forest, Illinois.
Susan
S
Reid
Global Clinical Development, Hospira, a Pfizer company, Lake Forest, Illinois.
Nancy
N
Martin
D000328:Adult; D019540:Area Under Curve; D059451:Biosimilar Pharmaceuticals; D000068817:Epoetin Alfa / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics / Q000627:therapeutic use; D004921:Erythropoietin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007279:Injections, Subcutaneous; D008297:Male; D055815:Young Adult
D059451:Biosimilar Pharmaceuticals; D004921:Erythropoietin; D000068817:Epoetin Alfa
biosimilar; epoetin alfa; equivalence; erythropoietin; pharmacodynamics pharmacokinetics